Related Experiment Video

Updated: Aug 5, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

ACK family tyrosine kinases as potential therapeutic targets for cancer

Radhika Mittal1, Priya Priya1, Jyotirmoy Banerjee2

  • 1Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, New Delhi, India.

Expert Opinion on Therapeutic Targets
|July 27, 2026
PubMed
Abstract

Insights

The activated Cdc42-associated kinase (ACK) family, including ACK1 and TNK1, are key in cancer signaling and epigenetic changes. Targeting these kinases offers new therapeutic strategies for difficult-to-treat malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • The activated Cdc42-associated kinase (ACK) family, comprising TNK1 and ACK1/TNK2, are crucial regulators of oncogenic signaling and epigenetic reprogramming.
  • ACK1 is frequently elevated in malignancies, acting as a cytoplasmic transducer and nuclear epigenetic modifier, influencing cell survival, therapy resistance, and immune evasion.
  • TNK1 primarily functions through ubiquitin-mediated signaling, P activation, and STAT-dependent pathways in hematological cancers.

Purpose of the Study:

  • To comprehensively review the ACK family's structure, regulation, epigenetic roles, and involvement in various cancers.
  • To evaluate targeted therapies, including selective inhibitors, dual agents, and combination strategies for ACK kinases.
  • To highlight the therapeutic potential of targeting ACK family members for cancer treatment.

Main Methods:

  • Review of existing literature on ACK kinase family members (TNK1, ACK1/TNK2).
  • Analysis of structural features, regulatory mechanisms, and epigenetic functions.
  • Evaluation of current and emerging therapeutic strategies, including targeted therapies and immunotherapy.

Main Results:

  • ACK kinases possess unique structural features, making them distinct therapeutic targets.
  • ACK1 and TNK1 present complementary therapeutic opportunities for parallel clinical development.
  • Understanding ACK family mechanisms is vital for developing effective targeted therapies.

Conclusions:

  • Targeting the unique structure of ACK kinases offers a distinct strategy for selective inhibition.
  • The parallel clinical development of ACK1/TNK2 and TNK1 is scientifically justified and timely.
  • Further research into the ACK family's epigenetic framework is needed for biomarker-driven selection and enhanced mechanistic understanding, potentially leading to new treatments for challenging cancers.
Keywords:
ACK1/TNK2TNK1cancer stem cellsepigenetic regulationhistone phosphorylationimmunotherapy resistancekinase inhibitorstargeted therapy

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...